ArticleFrontiers in bioengineering and biotechnology2025
Application of tergitol in liver decellularization and bioink preparation based on the obtained extracellular matrix.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Parameter Optimisation in 3D Extrusion Printing of Polyhydroxybutyrate Using Design of Experiment Methodology.Journal of functional biomaterials · 2026Article
- New frontiers in porcine atrioventricular node decellularization: preserving extracellular matrix architecture for biological scaffolds.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biological materials derived from decellularized tissues are of great interest in the field of tissue engineering. Artificial organoids can be used in drug discovery or toxicological studies, potentially reducing the reliance on animal models. They also serve as valuable models for cancer and virology research. In the study, 13 slightly different detergent-enzymatic decellularization processes were performed. The end products of each process were evaluated for their DNA content, residual lipids, sulfated glycosaminoglycans (sGAG), collagen and detergent residues. To our knowledge, for the first time, Tergitol was used in liver decellularization. A method for detecting residual Tergitol content in the matrix was also developed. A significant reduction in DNA and fat content was achieved, as well as preservation of collagen. However, a marked loss of sGAGs was observed. The most promising variant involved gradient decellularization using Tergitol and ammonium hydroxide combined with pre-digestion by trypsin, which yielded the most favorable results and showed no cytotoxicity. A bioink was subsequently formulated from the decellularized matrix, which has potential applications in 3D bioprinting of artificial liver tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.